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A B S T R A C T
Purpose: As important ion channels of the central nervous system, calcium channels not only take part in
epileptogenesis but also act as the targets of commonly used antiepileptic drugs (AEDs). Thus, this study
aimed to provide the ﬁrst investigation of the association between CACNA1A, CACNA1C, and CACNA1H
single nucleotide polymorphisms (SNPs) and AED resistance in the Chinese Han population.
Methods: We performed genotyping of tagging single nucleotide polymorphisms (tagSNPs) of CACNA1A,
1C and 1H in 480 Chinese epilepsy patients (288 drug-responsive and 192 drug-resistant patients). The
Illumina GoldenGate BeadArray assay was used to detect the genotypes of all of the patients. A total of 15
SNPs were selected based on the HapMap database. The genotype distributions in drug-responsive and
drug-resistant patients were compared, and the haplotype frequencies of each gene were calculated.
Results: None of the 15 tagSNPs alleles were found to be associated with drug-resistant epilepsy.
However, the frequency of the TAGAA haplotype in CACNA1A was signiﬁcantly higher in drug-resistant
patients than in drug-responsive patients after the correction of multiple comparisons with Bonferroni’s
method (TAGAA 13.3% vs. 7.1%, OR = 2.129 [1.373–3.299], P = 0.00059 < 0.05/10).
Conclusions: This study revealed no association between the 15 tagSNPs of CACNA1A, 1C, and 1H and
drug efﬁcacy in the Chinese Han population. The TAGAA haplotype of CACNA1A may be a risk factor for
AED resistance.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is a common, episodic and chronic neurological illness
that affects at least 60 million people worldwide [1]. In China,
approximately 9 million individuals suffer from epilepsy [2]. The
administration of the antiepileptic drugs (AEDs) is currently the
primary approach for controlling epileptic seizures [3]. Although
more than 15 new AEDs have become clinically available over the
past 20 years, 30% of patients remain resistant to AEDs, which can
seriously impact the patients’ psychology and cast a heavy burden
on the family and society [4]. It remains unclear why such a large
proportion of epilepsy patients develop resistance against AEDs. It
has been postulated that altered sensitivity and afﬁnity of the* Corresponding author. Tel.: +86 0731 84328888; fax: +86 0731 84327332.
E-mail address: boxiaomd@126.com (B. Xiao).
http://dx.doi.org/10.1016/j.seizure.2015.05.013
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights remolecular targets to the AEDs may account for the occurrence of
drug resistance [5].
The targets of AEDs include neurotransmitter receptors,
transporters, metabolic enzymes, and ion channels, such as
sodium, calcium, and potassium channels [6]. Voltage-gated
calcium channels contribute to the membrane potential behaviour
of neurons, participate in rhythm generation [7] and are regarded
as putative targets for many antiepileptic drugs, such as
carbamazepine, ethosuximide, lamotrigine, oxcarbazepine, phe-
nytoin, zonisamide, felbamate, gabapentin, topiramate, phenobar-
bital and valproate [6,8,9]. We suggest that calcium channels,
which are important targets, may affect the AED response.
Calcium channels can be classiﬁed into L-, N-, P-, Q-, R- and
T-types based on their pharmacological proﬁles [10]. Many
commonly used AEDs act on L-, P/Q-, and T-type channels. P/Q-
type calcium channels, which are referred to as Cav2.1 channels,
are distributed in cerebellar Purkinje cells and pre-synaptic
membranes, and their pore-forming a1A subunit is encoded byserved.
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are primarily located in the postsynaptic dendrites [11], and its a1C
subunit, which directs the activity, is encoded by the CACNA1C
gene. Cav3.2 channels, a subtype of T-type channels, are expressed
at cell bodies and dendrites [12], and its a1H subunit is encoded by
the CACNA1H gene.
It is known that genetic factors may play an increasingly
important role in both the pathogenesis of epilepsy and AED
efﬁcacy [13]. Previous studies in genetic mouse models and
epilepsy patients have demonstrated that dysfunction of the
CACNA1A gene may be associated with epilepsy [14,15]. CACNA1H
has been identiﬁed as a susceptibility gene of childhood absence
epilepsy (CAE), particularly in Han Chinese population [16,17]. A
recent study noted an upregulation of the a1c subunit of Cav1.2 in
the hippocampal tissue of patients with temporal lobe epilepsy
(TLE), suggesting that CACNA1C may be involved in the pathogen-
esis of TLE [18]. In addition, a number of association studies have
revealed that single nucleotide polymorphisms (SNPs) may be
predictors of AED resistance. For instance, in sodium channels,
which are also targets of AEDs, rs3812718 [19] in the SCN1A gene
has been proved to be associated with drug-resistant epilepsy.
The above-mentioned three types of calcium channels not only
play an important role in epileptogenesis but also act as the targets
of commonly used AEDs. However, to date, the relationship
between polymorphisms of calcium channel genes and AED
efﬁcacy has not yet been investigated. In this study, we aimed
to determine the association between CACNA1A, CACNA1C, and
CACNA1H SNPs and resistance of AEDs in the Chinese Han
population.
2. Materials and methods
2.1. Ethical approval
This study was approved by the Ethics Committee of Xiangya
Hospital, Central South University. All of the patients or their
parents were provided informed written consent before enrolment
in this study.
2.2. Subjects
A total of 480 outpatients suffering from idiopathic epilepsy were
recruited (301 males, 179 females, mean age: 23.6  13.4 years) from
Xiangya Hospital, the Second Xiangya Hospital of Central South
University and Hunan Provincial People’s Hospital. The patients were
diagnosed and classiﬁed based on the guidelines of the International
League Against Epilepsy (ILAE, 2010). The exclusion criteria included
severe adverse drug reactions, unreliable records of seizure frequency,
poor compliance with AEDs, cerebral trauma, tumour and infection,
cerebrovascular disorders, cerebral immunologic disorders, degenera-
tive and other neurological disorders, signiﬁcant psychiatric comor-
bidity, presence of progressive systemic disorders and history of
alcohol or drug abuse. A standardized questionnaire was administered
to collect demographic details and clinical data, which included seizure
types and frequencies, electroencephalography (EEG), magnetic
resonance imaging (MRI), past medical history, AED history, concomi-
tant drug history, and relevant family history. All AEDs used were
appropriately chosen for each patient based on the seizure type or
epilepsy syndrome.
2.3. Phenotyping
The phenotypes of AED responsiveness and resistance were
deﬁned on two levels according to the consensus deﬁnition
proposed by the ILAE in 2010 [20]. The ﬁrst level evaluates the
efﬁcacy of each antiepileptic drug and classiﬁes the results duringthe evaluation period, which is at least three times the longest
inter-seizure interval prior to starting a new intervention and not
less than 12 months, into the general categories ‘‘seizure-free,’’
‘‘treatment failure,’’ and ‘‘undetermined’’. The second level
provides a core deﬁnition of drug-resistant epilepsy. Drug
responsiveness was deﬁned as a successfully seizure-free evalua-
tion period, and drug resistance was deﬁned as failure of adequate
trials of two appropriate tolerated antiepileptic drug schedules
(whether as monotherapies or in combination) to achieve a
sustained period free of seizures. The types of epileptic seizures
and the appropriate use of antiepileptic drugs were decided by at
least two experienced attending physicians according to the
patient’s condition and auxiliary examinations.
2.4. Genotyping
The DNA from the peripheral blood of the participants was
isolated using the phenol-chloroform method. The tagSNPs in
CACNA1A, 1C and 1H were selected based on the HapMap database
(http://www.Hapmap.org/) by applying the CHB data source
(Chinese Beijing; SNP genotype data Rel 27 phase II+III, Feb09). In
the HapMap database, CACNA1A was selected and zoomed out 10%
to include the ﬂanking regions, resulting in a length of 329.1 kbp
from positions 13,164,155–13,493,276 on chromosome 19.
CACNA1C was also zoomed out 10% to show 709.1 kbp from
positions 2,000,493–2,709,608 on chromosome 12. Similarly,
CACNA1H was zoomed out to show 75.38 kbp from positions
1,139,815–1,215,198 on chromosome 16. The SNP genotype data
from HapMap corresponding to those regions were downloaded.
The Haploview software (version 4.20) was used to analyze the
data and combined with the NCBI (National Centre for Biotech-
nology Information) dbSNP database to select the SNPs according
to a comprehensive consideration of the following criteria: (1) a
minor allele frequency (MAF) greater than 5% in the HapMap CHB
population; (2) a r2 threshold of 0.8 and a logarithm of odds
threshold for multi-marker tests of 3; (3) validated functions for
the promoter, exons, splice sites of introns or 30-untranslated
region (30-UTR); and 4) an Illumina (USA) SNP score of all of these
loci greater than 0.6. The information of the ﬁltered SNPs is
presented in Table 1. All of the selected SNPs were in accordance
with Hardy–Weinberg equilibrium in the Chinese Han popula-
tion. Genotype detection was performed through the Illumina
GoldenGate BeadArray assay.
2.5. Statistical analysis
The SPSS software package (version 20.0 for Windows) was
used for the statistical analyses. The ages of the drug-responsive
and drug-resistant patient groups was compared by Student’s
t-test. The gender and other characteristics of the patients were
compared by x2 test. The relationship between the genotypes and
phenotypes were examined by binary logistic regression. The
linkage disequilibrium and haplotypes were analyzed using SHEsis
(http://analysis.bio-x.cn/myAnalysis.php). With a test level a of
0.05, the p-value <0.05 was accepted to deﬁne statistical
signiﬁcance. Bonferroni’s method was used for the correction of
multiple comparisons.
3. Results
The study population consisted of 288 AED responders
(23.3  14.3 years) and 192 resistant patients (24.2  11.8 years).
There was no signiﬁcant difference in the distributions of age, sex,
initial seizure frequency and seizure types between the two groups.
The most commonly used AEDs was valproic acid (42.7%), followed
by oxcarbazepine (27.7%), lamotrigine (25.4%), phenytoinum (14.8%),
Table 1
Basic characteristics of the selected SNPs in the CACNA1A, CACNA1C, and CACNA1H genes.
SNPs Genes Alleles MAF (%) Location Function Final score
rs2074880 CACNA1A T/G 40 Intron 0.917
rs10416717 CACNA1A G/A 48 Intron 0.852
rs7254351 CACNA1A G/T 30 30-UTR 0.693
rs16030 CACNA1A A/G 11 Exon Synonymous 0.847
rs2248069 CACNA1A A/G 44 Exon Synonymous 0.874
rs2239128 CACNA1C C/T 50 Intron 0.677
rs215976 CACNA1C G/A 38 Exon Synonymous 1.100
rs7316246 CACNA1C G/A 9 30-UTR 0.817
rs216008 CACNA1C G/A 39 Exon Synonymous 0.739
rs12813888 CACNA1C T/G 30 Exon Missense 0.600
rs1054645 CACNA1H T/C 12 Exon Missense 1.100
rs3794619 CACNA1H T/C 13 Intron 0.844
rs7191246 CACNA1H C/G 16 Intron 0.714
rs11640796 CACNA1H A/G 43 Intron 0.751
rs3751664 CACNA1H C/T 7 Exon Missense 0.698
Allele, major/minor allele. MAF, minor allele frequency.
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(Table 2). We detected ﬁve tagSNPs in CACNA1A, ﬁve tagSNPs in
CACNA1C, and ﬁve tagSNPs in CACNA1H in the drug-resistant
and drug-responsive patients, and we found no signiﬁcant
difference in the distribution of genotype and allele frequencies
(Table 3).
The linkage disequilibrium tests of the SNPs in CACNA1A, 1C and
1H are shown in Figs. 1–3, respectively. The rs2074880 and
rs16030 loci in CACNA1A were in strong linkage disequilibrium
(D‘ = 0.777). The rs215976 and rs216008 loci in CACNA1C were in
strong disequilibrium (D‘ = 0.742). In addition, the rs7191246 and
rs3794619 loci in CACNA1H were in strong disequilibrium
(D‘ = 0.871).
The haplotype calculation revealed that the frequency of the
TAGAA haplotype in CACNA1A was signiﬁcantly higher in the
drug-resistant patients than in the drug-responsive patients
after the correction of multiple comparisons with Bonferroni’s
method (TAGAA 13.3% vs. 7.1%, OR = 2.129 [1.373–3.299],
P = 0.00059 < 0.05/10 as shown in Table 4. We did not ﬁnd
statistic signiﬁcant haplotypes in CACNA1C and CACNA1H.Table 2
Demographic and clinical characteristics of drug-responsive and drug-resistant patient
Characters Drug-responsive (n = 288) 
Mean age  SD (years) 23.3  13.4 
Male 176 (61.1%) 
Age at the onset (years) 14.1  6.5 
Epilepsy duration(years) 5.4  4.6 
AEDs used in patients (%)
Carbamazepine 96 (35.2%) 
Valproic acid 75 (27.5%) 
Oxcarbazepine 92 (33.7%) 
Lamotrigine 49 (17.9%) 
Levetiracetam 27 (9.9%) 
Topiramate 25 (9.2%) 
Phenytoinum 20 (7.3%) 
Phenobarbital 18 (6.6%) 
Seizure type (%) 
Simple partial 111 (38.5%) 
Complex partial 81 (28.1%) 
Secondarily generalized 40 (13.9%) 
Generalized 56 (19.5%) 
Initial seizure frequency 
Daily 30 (10.4%) 
>1/week 77 (26.7%) 
1–4/month 92 (32.0%) 
<1/month 58 (20.1%) 
<1/half a year 31 (10.8%) 4. Discussion
Genetic polymorphisms can alter the drug metabolism at
various stages, including the absorption, distribution, transport,
action, metabolism and clearance of AEDs [1]. A large number of
association studies have attempted to analyze the pharmacoge-
nomics of resistant epilepsy with respect to drug transporters
(ABCB1 and ABCC2), drug targets (mainly focusing on sodium
channels), GABA pathways, the cytochrome p450 family and even
inﬂammatory factors [21]. However, there remains a large gap
between the high incidence of drug-resistant epilepsy and the
genetic variants that have been explored.
It has been proven that Cav2.1 channels play a crucial role in
modulating neurotransmitter release. Dysfunction of these chan-
nels may impair the balance between neuronal inhibition and
excitation leading to burst ﬁring [14]. Cav1.2 not only regulates
transcription by activating the transient inward calcium current
but also participates in neural development and plays an
important role in coupling neuronal excitation with Cav1.2-
mediated Ca2+ signalling, which makes Cav1.2 an effectives.
Drug-resistance (n = 192) Sum (n = 480) p-Value
24.1  13.4 23.6  13.4 0.574
125 (65.1%) 301 0.672
12.4  5.9 0.33
7.2  4.2 0.07
62 (30.0%) 158 (32.9%)
130 (62.8%) 205 (42.7%)
95 (45.9%) 187 (39.0%)
73 (35.3%) 122 (25.4%)
37 (17.9%) 64 (13.3%)
13 (6.3%) 38 (7.9%)
51 (24.6%) 71 (14.8%)
22 (10.6%) 40 (8.3%)
0.62
70 (36.5%) 181 (37.7%)
51 (26.6%) 132 (27.5%)
24 (12.5%) 64 (13.3%)








Genotype frequencies of the 15 SNPs in drug-responsive (n = 288) and drug-resistant patients (n = 192).






A/B AA AB BB AA AB BB p-Value Drug responsive A:B OR (95%CI) p-Value
CACNA1A rs2074880 T/G 62 86 44 90 151 47 0.13 210/174; 331/245 1.12(0.86–1.45) 0.40
rs10416717 G/A 59 86 47 60 152 76 0.23 180/204; 272/304 0.99(0.76–1.28) 0.92
rs7254351 G/T 68 99 22 109 152 27 0.71 235/143; 370/206 0.91(0.70–1.20) 0.52
rs16030 A/G 147 43 2 229 56 3 0.74 337/47; 514/62 0.86(0.58–1.29) 0.48
rs2248069 A/G 65 104 23 102 151 35 0.93 234/150; 355/221 0.97(0.75–1.27) 0.97
CACNA1C rs2239128 C/T 41 86 62 55 123 107 0.55 168/210; 233/337 1.16(0.89–1.50) 0.28
rs215976 G/A 112 70 10 136 128 24 0.05 294/90; 400/176 0.70(0.52–0.93) 0.016
rs7316246 G/A 154 37 1 226 59 3 0.78 345/39; 511/65 0.89(0.58–1.35) 0.78
rs216008 G/A 85 80 27 108 149 31 0.09 250/134; 365/211 0.92(0.70–1.21) 0.58
rs12813888 T/G 105 74 13 139 128 21 0.38 284/100; 406/170 0.84(0.63–1.12) 0.24
CACNA1H rs1054645 T/C 153 33 6 211 72 5 0.09 339/45; 494/82 0.80(0.54–1.18) 0.26
rs3794619 T/C 154 33 4 207 74 6 0.09 341/41; 488/86 0.68(0.46–1.01) 0.06
rs7191246 C/G 177 11 4 243 42 3 0.007 365/19; 528/48 1.75(1.01–3.02) 0.04
rs11640796 A/G 33 89 70 31 143 112 0.13 155/229; 205/367 1.21(0.93–1.58) 0.16
rs3751664 C/T 159 27 5 227 58 3 0.12 345/37; 512/64 1.17(0.76–1.79) 0.48
Homozygous wild-type patients served as the reference group. OR, odds ratio; CI, conﬁdence interval.
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generally open and close at approximately similar membrane
potentials, which can be activated rapidly at low voltages, leading
to depolarization of the membrane and the generation of low
threshold spikes (LTS) involved in ‘‘burst ﬁring’’ and thalamocor-
tical synchronization oscillation, which may have a close
relationship with epilepsy [22]. AEDs are thought to generate
antiepileptic effects through calcium channels by altering the
calcium inﬂux, inﬂuencing the excitability of neurons and
potentially regulating the balance of neurotransmitters [23,24].
In this study, we aimed to determine the association between
common variations of the CACNA1A, 1C, and 1H genes and AED
resistance in the Chinese Han population. However, we found no
statistically signiﬁcant difference between the 15 SNPs of the three
genes and drug-resistant epilepsy. However, interestingly, we
found a meaningful haplotype in CACNA1A, namely TAGAA, whichFig. 1. Linkage disequilibrium of ﬁve tagSNPs in the CACNA1A gene in all of the
patients. The linkage disequilibrium between the pairs of polymorphisms is shown
in the diamonds (D0), with darker shading indicating a greater D0 .may be a risk factor for AED resistance. To the best of our
knowledge, the processes of drug-resistance can be inﬂuenced by
various genes, environmental factors and their interactions.
Because single nucleotide polymorphisms (SNPs) are limited, we
also analyzed the haplotypes of the three genes. Although the exact
mechanism remains unknown, some published reports have
shown that dysfunction of calcium channels can inﬂuence the
calcium ion ﬂow and further impact the receptors, which may be
the underlying cause of drug-resistant epilepsy. More speciﬁcally,
calcium ion ﬂow changes can cause stochastic lesions of
mitochondrial DNA and affect non-transcriptional or posttran-
scriptional processes, which may potentially alter the sensitivity of
drug targets and thereby increase the likelihood of drug resistance
[25].
Calcium channels play an important role in the generation of
epilepsy, participate in antiepileptic processes and may even affect
the plasticity of receptors. To improve the accuracy of the group,Fig. 2. Linkage disequilibrium of ﬁve tagSNPs in the CACNA1C gene in all of the
patients.
Table 4
Frequencies of haplotypes (>3%) containing all polymorphisms in the CACNA1A gene in drug-responsive (n = 288) and drug-resistant epileptic patients (n = 192).
Genes Frequency p-Value Odds ratio (95%CI)
Haplotype Resistant Responsive Fisher’s p value Pearson’s p value
CACNA1A
GAGAA 0.082 0.075 0.554 0.554 1.157(0.714  1.876)
GAGAG 0.052 0.064 0.504 0.504 0.825(0.469  1.542)
GATAA 0.040 0.055 0.381 0.381 0.756(0.404  1.415)
GGGAA 0.116 0.153 0.159 0.159 0.755(0.511  1.117)
GGGAG 0.035 0.024 0.263 0.263 1.547(0.717  3.338)
*TAGAA 0.133 0.071 0.00059 0.00059 2.129(1.373  3.299)
TAGAG 0.026 0.011 0.561 0.561 0.793(0.362  1.736)
TAGAG 0.068 0.068 0.876 0.876 1.042(0.621  1.747)
TGGAA 0.047 0.038 0.390 0.390 1.324(0.697  2.514)
TGTAA 0.054 0.076 0.235 0.235 3.312(1.506  7.284)
All of the frequencies less than 0.03 were ignored in the analysis.
* p < 0.05/10.
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responsiveness according to the guidelines of the International
League Against Epilepsy (ILAE, 2010). In addition, because
epilepsy is a very complex neurological disease, we also analyzed
various subgroups, including partial seizure, generalized seizure
and non-classiﬁable seizure groups, and found no positive
association (data not shown). Several factors may explain our
results: First, because many AEDs appear to work through
multiple mechanisms and the inherited component of the
response to drugs is typically polygenic, it is complicated to ﬁnd
the real reason underlying drug resistance. Second, this study only
tested some of the SNPs and did not use a sequencing approach to
detect other potential SNPs or genetic variants within these genes.
Third, based on the limited sample size in our study, the MAF of the
selected SNPs was greater than 5%, and rare SNPs, which may play
an important role in AED resistance, were overlooked. Fourth,
different ethnic backgrounds should also be taken into account
because these may give rise to different SNP distributions. Thus,
additional data from different races should be collected in future
studies.Fig. 3. Linkage disequilibrium of ﬁve tagSNPs in the CACNA1H gene in all of the
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